Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

June 2022 | 86 pages | ID: HC774C042B6BEN
Global Markets Direct

Abstracts

Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Zoster (Shingles) – Drugs In Development, 2022, provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape.

Shingles (herpes zoster) is a painful, blistering skin rash. It is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain and swollen glands. The predisposing factors include age and weakened immune system. Treatment includes antihistamines and pain relievers.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Zoster (Shingles) – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Herpes Zoster (Shingles) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Zoster (Shingles) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 3, 5, 1, 13, 4 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Herpes Zoster (Shingles) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Zoster (Shingles) (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Herpes Zoster (Shingles) (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Herpes Zoster (Shingles) (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Zoster (Shingles) (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Herpes Zoster (Shingles) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Herpes Zoster (Shingles) – Overview
Herpes Zoster (Shingles) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Herpes Zoster (Shingles) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Zoster (Shingles) – Companies Involved in Therapeutics Development
Herpes Zoster (Shingles) – Drug Profiles
Herpes Zoster (Shingles) – Dormant Projects
Herpes Zoster (Shingles) – Discontinued Products
Herpes Zoster (Shingles) – Product Development Milestones
Featured News & Press Releases
May 16, 2022: NanoViricides reports update on Shingles drug
Jan 07, 2022: Adjuvance Technologies announces issuance of U.S. patent covering semi-synthetic saponin adjuvants
Mar 30, 2021: Curevo Vaccine announces the approval to conduct a phase 1b clinical trial in South Africa to evaluate safety and immunogenicity of its adjuvanted subunit investigational vaccine, CRV-101, against varicella (Chickenpox) in HIV-positive children
Sep 15, 2020: Curevo Vaccine announces robust antibody response results of Phase I clinical trial of investigational vaccine for Shingles CRV-101
May 14, 2020: NanoViricides provides update on drug candidate NV-HHV-101
Jan 09, 2020: NanoViricides successfully completes required genetic toxicology testing of lead Drug candidate NV-HHV-101
Jan 07, 2020: NanoViricides has initiated genetic toxicology testing required for an IND for its drug candidate
Dec 06, 2019: NanoViricides annual meeting of shareholders to be held on Saturday, December 7th, 2019 at the Sheraton Hotel, Stamford, CT
Dec 03, 2019: NanoViricides founder Dr. Diwan provides $2,000,000 loan commitment to the company
Dec 02, 2019: NanoViricides has initiated required safety pharmacology assessment of lead drug candidate towards IND
Nov 19, 2019: NanoViricides files quarterly report for period ending September 30, 2019 - HerpeCide drug candidate ind enabling studies update, progressing towards clinical trials
Oct 31, 2019: NanoViricides initiates required dermal sensitization and ocular irritation testing of lead drug candidate towards IND
Oct 09, 2019: NanoViricides has initiated bio-analytical studies as part of IND-enabling safety and toxicology studies of lead candidate NV-HHV-101
Oct 03, 2019: NanoViricides is creating nanomedicines to develop antiviral therapies to combat shingles and herpes viruses
Sep 26, 2019: Curevo Vaccine announces interim results of phase I clinical trial of CRV-101
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Herpes Zoster (Shingles), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Herpes Zoster (Shingles) – Pipeline by Adjuvance Technologies Inc, 2022
Herpes Zoster (Shingles) – Pipeline by AIM Vaccine Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by Amytrx Therapeutics Inc, 2022
Herpes Zoster (Shingles) – Pipeline by Beijing Green Bamboo Biotechnology Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by Beijing Northland Biotech Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by BioNTech SE, 2022
Herpes Zoster (Shingles) – Pipeline by CanSino Biologics Inc, 2022
Herpes Zoster (Shingles) – Pipeline by CHA Vaccine Institute Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by Changchun Bcht Biotechnology Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by Chengdu Maikekang BioTechnology Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by China National Pharmaceutical Group Corp, 2022
Herpes Zoster (Shingles) – Pipeline by Chongqing Zhifei Biological Products Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by CPL Biologicals Pvt Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by DongKoo Bio & Pharma Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by Dynavax Technologies Corp, 2022
Herpes Zoster (Shingles) – Pipeline by EyeGene Inc, 2022
Herpes Zoster (Shingles) – Pipeline by GC Biopharma Corp, 2022
Herpes Zoster (Shingles) – Pipeline by GeneOne Life Science Inc, 2022
Herpes Zoster (Shingles) – Pipeline by GreenLight Biosciences Holdings PBC, 2022
Herpes Zoster (Shingles) – Pipeline by GSK plc, 2022
Herpes Zoster (Shingles) – Pipeline by Jiangsu Recbio Technology Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by NAL Pharmaceuticals Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by NanoViricides Inc, 2022
Herpes Zoster (Shingles) – Pipeline by Shanghai Yidao Biological Technology Co Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by Shulov Innovative Science Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by SK Bioscience Ltd, 2022
Herpes Zoster (Shingles) – Pipeline by Vaccitech Plc, 2022
Herpes Zoster (Shingles) – Pipeline by Vapogenix Inc, 2022
Herpes Zoster (Shingles) – Pipeline by XBiotech Inc, 2022
Herpes Zoster (Shingles) – Dormant Projects, 2022
Herpes Zoster (Shingles) – Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Herpes Zoster (Shingles), 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022